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Abstract
Background: Despite the successful scale-up of ART services over the past years, long term retention in ART care
remains a major challenge, especially in high HIV prevalence and resource-limited settings. This study analysed the
short (<12 months) and long (>12 months) term retention on ART in two ART programmes in Malawi (Thyolo
district) and Zimbabwe (Buhera district).
Methods: Retention rates at six-month intervals are reported separately among (1) patients since ART initiation and
(2) patients who had been on ART for at least 12 months, according to the site of ART initiation and follow-up,
using the Kaplan Meier method. ‘Retention’ was defined as being alive on ART or transferred out, while ‘attrition’
was defined as dead, lost to follow-up or stopped ART.
Results: In Thyolo and Buhera, a total of 12,004 and 9,721 patients respectively were included in the analysis. The
overall retention among the patients since ART initiation was 84%, 80% and 77% in Thyolo and 88%, 84% and 82%
in Buhera at 6, 12 and 18 months, respectively. In both programmes the largest drop in ART retention was found
during the initial 12 months on ART, mainly related to a high mortality rate in the health centres in Thyolo and a
high loss to follow-up rate in the hospital in Buhera. Among the patients who had been on ART for at least 12
months, the retention rates leveled out, with 97%, 95% and 94% in both Thyolo and Buhera, at 18, 24 and 30
months respectively. Loss to follow-up was identified as the main contributor to attrition after 12 months on
treatment in both programmes.
Conclusions: To better understand the reasons of attrition and adapt the ART delivery care models accordingly, it
is advisable to analyse short and long term retention separately, in order to adapt intervention strategies
accordingly. During the initial months on ART more medical follow-up, especially for symptomatic patients, is
required to reduce mortality. Once stable on ART, however, the ART care delivery should focus on regular drug refill
and adherence support to reduce loss to follow up. Hence, innovative life-long retention strategies, including use of
new communication technologies, community based interventions and drug refill outside the health facilities are
required.
Keywords: Retention, ART, HIV, SSA, Resource-limited settings, Short and long term
* Correspondence: frasschaert@itg.be
1Institute of Tropical Medicine, Nationale straat 155, Antwerpen 2000,
Belgium
Full list of author information is available at the end of the article
© 2012 Rasschaert et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Rasschaert et al. BMC Health Services Research 2012, 12:444
http://www.biomedcentral.com/1472-6963/12/444
Background
Access to antiretroviral therapy (ART) continues to ex-
pand rapidly worldwide, especially in Sub-Saharan Africa
(SSA) with a 30-fold increase in ART coverage since the
end of 2003 [1]. This rapid ART scale-up process was
facilitated through decentralisation of ART services, task
shifting and involvement of the community in care deliv-
ery [2-5]. For those fortunate enough to receive ART,
HIV/AIDS became a chronic life-long disease. Long
term retention in ART care remains however a major
challenge, particularly in SSA countries with limited
resources and a severe shortage of health staff [2].
Two successive systematic reviews on retention in
ART care showed a positive trend in overall retention
rates over the past three years [6,7]. The first analysis
(2007) reported a 62% retention rate at 24 months of
treatment, in the later analysis (2010) this rate increased
to 76%, probably due to the increased experience in
handling large ART cohorts and a better tracing system
for patients missing from care. Both analyses found a
lower retention rate in patients recently initiated on
ART (≤12m), mainly due to a high early mortality rate,
whereas in the older cohorts the main reason for attri-
tion was patients defaulting treatment [8,9]. Therefore it
might be advisable to separate cohort analyses in short
(≤12m) and long term (>12m) retention in care as they
may require different types of interventions.
This study analysed the short and long term retention
among the patients started on ART in two ART pro-
grammes supported by Médecins Sans Frontières (MSF)
in Malawi, Thyolo district, and Zimbabwe, Buhera dis-
trict, by separating the patients since ART initiation (in-
cluding patients ≤12 months on ART) from the patients
who had been on ART for at least 12 months.
Methods
Study setting and population
MSF started HIV projects in close collaboration with the
Ministry of Health in Thyolo, one of the poorest districts
in Southern Malawi, in 1997 and in Buhera, a poor rural
district in the South-east of Zimbabwe, in 2004. Thyolo
district has a population of 587,455 habitants, with an
HIV prevalence of 14.0%, and 82,250 people living with
HIV/AIDS (PLWHA) of whom 16,450 are estimated in
urgent need of ART. Buhera district, with a population
of 223,382 inhabitants, has an HIV prevalence of 19.7%,
and 44,000 PLWHA of whom 8,800 are estimated in ur-
gent need of ART, according to the WHO ART eligibil-
ity criteria – 2006 (Table 1).
In both settings the health systems are weak, facing se-
vere human resources for health shortages and, infra-
structure and drug supply problems. In Thyolo and
Buhera, ART was initially introduced at the district hos-
pitals in 2003 and 2005, respectively. In 2006, ART care
activities were decentralised to the peripheral health
centres in both programmes to enable ART scale-up.
This process implied shifting towards a public health ap-
proach with integration of ART services into the health
centres, shifting of tasks to lower health cadres and
increased community involvement. In both settings, the
decentralisation process resulted in a steep increase in
patients accessing ART. By December 2009, the pro-
grammes in Thyolo and Buhera counted respectively
15,016 and 9,721 patients on treatment (Figure 1). Both
programmes involved community health care workers to
trace patients who did not show up at their scheduled
appointment.
All HIV infected patients, aged 15 years or older at the
time of ART initiation were included in the analysis.
They were divided into two or three groups according to
the place of ART initiation and follow-up: (1) patients
initiated and followed up in the hospital, (2) patients
initiated and followed up in the health centres and (3)
patients initiated in the hospital and later referred to the
health centres. In Thyolo, patients referred from the
hospital to the health centres were classified as trans-
ferred out. They could not be retrieved, however, as the
datasets of the different sites could not be merged.
The study period of the two programmes differs de-
pending on the data available. For both settings, the
Table 1 Malawi and Zimbabwe: Population and HIV-related indicators, 2009
Malawi [10] Thyolo [10] Zimbabwe [11] Buhera [11]
Total population 15 million 587455 13.4 million 223382
HIV prevalence (15–45 years-old) 11.9% 14.0% 14.3% 19.7%
Total people living with HIV/AIDS 1785000 82250 1916200 44000
People in need of ART – CD4<200 cells/mm3 305805 16450 389895 8800
Active and alive on ART 198864 15016 218589 9721*
Year Start HIV programme 1997 2004
Year ART implementation 2003 2005
Year Decentralisation ART activities 2006 2006
* Buhera district attracts a large proportion of PLWHA from neighbouring districts.
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patients were included from the start of the ART avail-
ability (2003, Thyolo and 2005, Buhera) till September
2008 for Thyolo and December 2009 for Buhera.
Data collection
In the district hospital of Thyolo, all the patients regis-
tered in the programme and initiated on ART are moni-
tored through an electronic database, FUCHIA (Follow
Up and Care of HIV infection and AIDS, Epicentre-
MSF). In the decentralised ART sites, standardised and
simplified monitoring tools – patients’ registers, master
cards and individual identity cards – were used to moni-
tor the ART outcomes [12].
In Buhera, a parallel monitoring system has been
maintained over the past years. A paper-based system
was used with several registers plus an electronic data-
base system (FUCHIA), where patients in the decentra-
lised ART sites were reported on a six-monthly basis.
Data analysis
In both programmes, treatment outcomes are defined
as: (1) ‘alive and on ART’ – patients initiated on ART
and still followed up in one of the health facilities, (2)
‘died’ – patients who have died for any reason while on
ART, (3) ‘lost to follow-up’ – patients on ART who have
not attended the clinic for three months since the last
scheduled appointment date, according to the national
guidelines in both countries [13], (4) ‘stopped’ – patients
who have stopped ART for any reason, (5) ‘transferred
out’ – patients who have been transferred permanently
to another health facility. For this analysis, ‘retention’ in
care refers to ‘patients who are alive and on ART’.
Patients who were transferred out are considered to be
retained until the date of transfer at which time they are
censored from the analysis. ‘Attrition’ is defined as dis-
continuation of ART for any reason, which includes
died, lost to follow-up or stopped treatment.
An initial ART retention analysis was performed
from the date of ART initiation. A second analysis
examined the retention among patients on ART for at
least 12 months in both programmes, with the start
date of analysis 12 months on ART. Twelve months
was chosen as cut-off point as previous studies had
shown a difference in retention between ≤ 12 months
and > 12 months on ART [6,7]. The end date of both
analyses was set at 30 and 48 months on ART for the
patients in Buhera and Thyolo respectively, to ensure a
sufficient number of patients in the analysis at each
time-point of treatment.
The Kaplan-Meier method was used to assess the
probability of retention in ART care among the patients
in both ART programmes (1) from ART initiation and
(2) at least 12 months on ART, according to the initi-
ation and follow-up site of ART (hospital or health cen-
tres). Baseline characteristics were described using
medians and interquartile range (IQR) for continuous
variables and counts and percentage for categorical vari-
ables. The characteristics were compared between the
patient groups using the chi-square test for categorical
variables and the Kruskal-Wallis test for continuous
variables.
A multivariate Cox-regression model was used to esti-
mate hazard ratios (HR) for the treatment outcomes,
adjusting (aHR) for the following potential confounders:
age, start year ART, gender and ART eligibility stage. All
significant factors, with P-value <0.2, were included in
this multivariate analysis for each programme.
Data analysis was done using STATA 10 (StataCorp
LP, College Station, TX, USA).
Ethics assessment
Both the Malawian and Zimbabwean ministry of health
provided general oversight and approval for the collec-
tion and use of routine programme data for the moni-
toring and evaluation, therefore ethical approval for
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Figure 1 Total number of patients, active on ART per year – Thyolo–Malawi, 2003–2009 and Buhera–Zimbabwe, 2005–2009.
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the type of analysis conducted in this study was not
required.
Results
In Buhera and Thyolo, respectively 9,721 and 12,004
adults were initiated on ART during the study period.
In both ART programmes, respectively 74.7% and 82.5%
of the patients, who had been on ART for at least 12
months, were initiated on treatment at hospital level.
Patient characteristics
Tables 2 and 3 present the baseline characteristics of
the patients on ART, at ART initiation in the district
hospital and health centres in both settings. The me-
dian age was 37 years (IQR 31–45) and 35 years (IQR
29–41), in Buhera and Thyolo respectively. In both
programmes, more female patients were registered in
the health centres and the proportion of patients in
WHO stage 4 was higher in the hospitals.
Retention
Table 4 shows the difference in retention rate among the
patients (1) from ART initiation and (2) at least 12
months on ART according to the ART initiation and
follow-up site. In both settings, the highest drop in re-
tention rate is noticed during the first 12 months on
ART.
In Buhera, it was found that the patients initiated and
followed up in the health centres had a 50% overall
decrease in attrition hazard compared to those in the
hospital (aHR 0.50, 95%CI 0.45-0.59; p-value <0.001). In
Thyolo, the patients initiated on ART and followed up in
the health centres had a 23% overall increase in attrition
hazard, after adjustment for age, gender, ART eligibility
stage and start year compared to the patients in the
hospital (aHR 1.23, 95%CI 1.12-1.36, p-value <0.001).
(Figure 2A-C).
Considering only the patients who had been on ART
for at least 12 months, the attrition hazard among the
patients initiated in the health centres (aHR 0.58, 95%CI
0.47-0.72, p-value<0.001) and those referred to the
health centres (aHR 0.34, 95%CI 0.24-0.47, p-value
<0.001) was found to be significantly lower than the
hazard of the patients in the hospital in Buhera. The
patients initiated on ART in the hospital and later re-
ferred to the health centres had a lower attrition haz-
ard compared to those initiated on ART in the health
centres (aHR 1.77, 95%CI 1.17-2.69, p-value 0.007). In
Thyolo, the attrition hazard was higher in the health
centres than in the hospital after adjusting for age,
gender, ART eligibility and start of ART year (aHR
1.59, 95%CI 1.25-2.09, p-value <0.001) (Figure 2B-D).
Lost to follow up and mortality
In Thyolo, the proportion of deaths among the patients
on ART in the health centres decreased from 13.5%
(2006) to 6.2% (2008), while the proportion of patients
lost to follow up increased from 0.4% (2006) to 3.6%
Table 2 Baseline characteristics of patients on ART at ART initiation in health facilities, Thyolo-Malawi
Hospital Health centres Total
Total patients on ART 8902 (74%) 3102 (26%) 12004
Gender
Male 3354 (38%) 962 (31%) 4316 (36%)
Female 5548 (62%) 2140 (69%) 7688 (64%)
Median age – IQR 34 (29–41) 35 (29–42) 35 (29–41)
WHO stage / CD4
WHO Stage 1–2 & CD4>200/mm3 193 (2%) 18 (0.6%) 211 (2%)
WHO stage 1–2 & CD4≤200/mm3 645 (7%) 31 (1%) 676 (6%)
WHO stage 1–2 & CD4 unknown 192 (2%) 139 (4%) 331 (3%)
Stage 3† 5581 (63%) 2522 (81%) 8103 (68%)
Stage 4† 2291 (26%) 392 (13%) 2683 (22%)
Start year of ART
2003 391 (100%) NA 391
2004 1058 (100%) NA 1058
2005 1439 (100%) NA 1439
2006 2281 (83%) 451 (17%) 2732
2007 2225 (62%) 1347 (38%) 3572
2008 1508 (54%) 1304 (46%) 2812
† Irrespective of CD4 count.
* CD4 counts were not reported separately as 68% of patients followed up in the health centres did not have CD4 counts. These are no longer done on WHO
stage 3 and 4 patients, according to the Malawian guidelines.
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(2008), with the growing cohort. Among the patients
initiated and followed up on ART in the hospital, both
the proportion of deaths (6.5% and 2.1%%) and lost to
follow up (4.0% and 2.7%) decreased respectively be-
tween 2006 and 2008.
In health centres in Buhera, the proportion of patients
deceased or lost to follow up increased with the growing
cohort respectively from 0.3% (2006) to 2.8% (2009) and
from 1.1% (2006) to 2.4% (2009). Among patients in the
hospital, the proportion of deaths (14.7% and 1.7%
Table 3 Baseline characteristics of patients on ART at ART initiation in health facilities, Buhera-Zimbabwe
Hospital Hospital – Health centres§ Health centres Total
Total patients on ART 3594 (37%) 1536 (16%) 4591 (47%) 9721
Gender
Male 1296 (36%) 444 (29%) 1512 (33%) 3252 (34%)
Female 2298 (64%) 1093 (71%) 3077 (67.1%) 6467 (67%)
Median age IQR 37 (31–44) 39 (32–47) 37 (31–45) 37 (31–45)
WHO stage / CD4
WHO Stage 1–2 & CD4>200/mm3 203 (6%) 115 (8%) 357 (8%) 675 (7%)
WHO stage 1–2 & CD4≤200/mm3 309 (9%) 171 (11%) 510 (11%) 990 (10%)
WHO stage 1–2 & CD4 unknown 145 (4%) 61 (4%) 402 (9%) 608 (6%)
Stage 3† 1792 (50%) 579 (49%) 2718 (59%) 5269 (54%)
Stage 4† 1140 (32%) 429 (28%) 594 (13%) 2163 (23%)
Start year of ART
2005 512 (100%) NA NA 512
2006 1133 (99%) 9 (1%) 1142
2007 1652 (67%) 784 (32%) 2436
2008 1218 (40%) 1795 (60%) 3013
2009 616 (24%) 2002 (76%) 2618
† Irrespective of CD4 count.
§ Hospital – Health centres are the patients who initiated ART in the hospital and were later referred to the health centres.
Table 4 Retention rates according to the time on ART, Thyolo–Malawi and Buhera-Zimbabwe
6m 12m 18m 24m 30m 36m 42m 48m
Patients from ART initiation
Thyolo
All patients 83.8% 79.7% 77.4% 75.8% 74.5% 73.3% 72.1% 70.9%
Health centres 81.7% 78.6% 76.0% 73.5% 72.8% - - -
District Hospital 84.5% 80.1% 77.8% 76.4% 75.0% 73.1% 72.1% 71.0%
Buhera
All patients 87.6% 84.1% 81.9% 80.1% 78.7%
Health centres 91.3% 88.6% 86.9% 85.2% 83.9%
Hospital – Health centre§ 97.5% 95.8% 94.3% 93.2% 92.3%
District Hospital 78.9% 73.5% 70.5% 68.2% 66.4%
Patients at least 12 months on ART
Thyolo
All patients - - 97.1% 95.2% 93.5%. 92.0% 90.5% 88.9%
Health centres - - 96.6% 93.5% 92.6% - - -
District hospital - - 97.1% 95.3% 93.7% 92.2% 90.6% 89.1%
Buhera
All patients - - 97.4% 95.3% 93.6%
Health centres - - 98.1% 96.2% 94.7%
Hospital – Health centre§ - - 98.5% 97.4% 96.4%
District Hospital - - 95.9% 92.7% 90.4%
§ Hospital – Health centres are the patients who initiated ART in the hospital and were later referred to the health centres.
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respectively) and lost to follow ups (6.7% and 5.6%) both
dropped between 2006 and 2009.
During the initial 12 months on ART, mortality was
the main contributor to attrition in both the hospital
and health centres in Thyolo. Hence, the probability of
mortality was found to be significantly higher among the
patients in the health centres (aHR 1.66, 95%CI 1.33-
2.09, p-value <0.001). No significant difference in ‘lost to
follow-up’ was found among the patients in the health
centres and hospital (aHR 0.81, 95%CI 0.59-1.12, p-value
0.209). While, in Buhera, the high defaulter rate was
found to be the main contributor to attrition. Patients
initiated on ART in the health centres (aHR 0.25, 95%CI
0.18-0.34, p-value <0.001) or referred to the health cen-
tres (aHR 0.14, 95%CI 0.08-0.26, p-value <0.001), were
found to have a decreased defaulter hazard compared to
those in the hospital. The probability of mortality was
lower for patients in the health centres than for the
patients in the hospital (HR 0.70, 95%CI 0.56-0.86,
p-value <0.001). The patients referred to the health centres
were found to have a lower hazard of dying compared to
those initiated on ART in the health centres (HR 0.47, 95%
CI 0.36-0.62, p-value <0.001) (Figures 3A-C and 4A-C).
Considering only the patients who had been on ART
for at least 12 months, no significant difference in the
probability of lost to follow-up was found between the
patients in the health centres and hospital in Thyolo
(HR 1.25, 95%CI 0.73-2.13, p-value 0.413). While in
Buhera, a significant difference in the probability of lost
to follow-up was found among the patients initiated in
health centres (aHR 0.42, 95%CI 0.31-0.58, p-value
<0.001) and those referred to the health centres (aHR
0.23, 95%CI 0.13-0.42, p-value <0.001) compared to the
patients in the hospital. In both programmes, no signifi-
cant difference in risk of mortality was found according
to the ART site after 12 months on ART (Thyolo - HR
Thyolo-Malawi
A. Probability of Retention in ART care 
–
0m B. Probability of Retention in ART care 
–
>12m
Buhera - Zimbabwe
C. Probability of Retention in ART care – 0m D. Probability of Retention in ART care – >12m
Figure 2 Probability of ART retention according to time on ART and ART site, Thyolo-Malawi and Buhera-Zimbabwe.
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1.23, 95%CI 0.74-2.05, p-value 0.416 and Buhera - HR 0.91,
95%CI 0.61-1.35, p-value 0.641) (Figures 3B-D and 4B-D).
In Buhera, the high proportion of patients on ART
lost to follow up and the uncertainty of their outcomes
might result in an underestimation of the mortality of
all patients started on ART in the hospital or health
centres. We used a web-based calculator using the
meta-method to correct estimates of mortality at 1
year for lost to follow up [14]. Among all patients on
ART in the hospital an uncorrected estimated mortal-
ity at 1 year of 14.9% (95% CI 12.6-17.2) and 1.7%
(95% CI 1.2-2.2) was reported in 2006 and 2009 re-
spectively. After correction, the estimates of mortality
increased to 17.7% (95% CI 14.8-20.8) and 4.9% (95 CI
3.1-6.6) respectively. In the health centres, the cor-
rected estimated mortality in 2009 increased from
1.7% (95 CI 2.4-3.2) to 4.2% (95CI 3.3-5) after adjust-
ing for lost to follow up.
Discussion
This analysis documents a major difference in retention
rates between patients during the first 12 months on
ART and patients who had been on ART for at least 12
months. In both programmes, the largest drop in reten-
tion in ART care was found during the initial 12 months
on ART. After 12 months on ART, the retention rates
flattened out in both settings.
Retention outcomes compared to other programmes
The results found in this analysis are similar to those
reported in previous studies. A meta-analysis of pub-
lished programmes in 13 Sub-Saharan countries
reported an average retention rate of 80.2% (12m), 76.1%
(24m) and 72.3% (36m) [6]. Other studies conducted in
Lesotho, Malawi and 11 countries in West Africa
revealed similar retention outcomes: respectively 74%,
80% and 76% at 12 months and 66%, 77% and 60% at
Thyolo - Malawi
Probability of Mortality while on ART – 0m Probability of Mortality while on ART – >12m
Buhera - Zimbabwe
Probability of Mortality while on ART – 0m
Probability of Mortality while on ART – >12m
0.
00
0.
05
0.
10
0.
15
0.
20
0 12 24 36 42 48
Time in months since starting ART
Hospital Health centres
0.
00
0.
05
0.
10
0.
15
0.
20
12 24 42 4836
Time in months since starting ART
Hospital Health centres
0.
00
0.
05
0.
10
0.
15
0 6 12 18 24 30
Time in months since starting ART
Hospital Hospital - Health centres
Health centres
0.
00
0.
05
0.
10
0.
15
12 18 24 30
Time in months since starting ART
Hospital Hospital - Health centres
Health centres
A B
DC
Figure 3 Probability of mortality while on ART according to time on ART and ART site, Thyolo-Malawi and Buhera-Zimbabwe.
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24 months [15-17]. The national ART programme in
Botswana reported survival estimates of 79.3% at 3
years on ART [18].
The main drop in retention on ART is noticed during
the initial months on ART. After 12 months, the reten-
tion rate levels out over time on ART [6,7]. During the
initial 12 months on ART, the contribution of mortality
to the attrition rate in Thyolo amounts to 65%. In
Buhera, however, 57% of the early attrition is related to
the high loss to follow-up rate, which might be related
to the rapid decentralisation, the lack of trained human
resources available in the health centres, and the poor
registration, which undoubtedly overlooked many self-
referrals of patients to the health centres as soon as the
ART services became available. After 12 months on
ART, loss to follow-up and mortality contribute equally
to the total attrition rates in Thyolo. In Buhera loss to
follow-up remains the major cause of attrition (70% at
30m). The high proportion of lost to follow-up might
lead to an underestimation of the mortality as well as
the retention on ART. Studies in South Africa, Malawi
and Zambia tracing defaulters found that 40-60% of
them died within the first three months after default-
ing [19-23], while other studies report that 20-80% of
the traceable patients lost to follow-up were still on
ART in other health facilities [24,25]. After taking into
account the estimated mortality among the patients
lost to follow up, the corrected mortality increased by
2.8% and 2.5% in the hospital of Buhera in 2006 and
2009, respectively.
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Figure 4 Probability of lost to follow up while on ART according to time on ART and ART site, Thyolo-Malawi and Buhera-Zimbabwe.
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Treatment outcomes according to ART sites
In Buhera, the retention rate (≤12m & >12m) was sig-
nificantly higher among the patients initiated on ART in
the health centres and among those referred to the
health centres for follow-up on ART compared to the
patients in the hospital (Figure 2C-D). In the latter
group, the retention outcomes were even better, al-
though a selection bias has to be taken into account as
these patients were most often stabilised in the hospital
before referral. These improved outcomes in the health
centres might be related to the increased proximity and
accessibility of the ART care delivery services. Obvious
socio-economic benefits are: faster enrolment in care,
lower transport cost and time-saving [26-28]. In Thyolo,
the outcomes during the initial 12 months on ART were
significantly better among the patients followed up in
the hospital, which is mainly due to the high early mor-
tality in the health centres (Figure 2A-B). The more
experienced health staff, more specialised care and better
availability of essential drugs at the hospital level could
explain this. However, after 12 months on ART no sig-
nificant difference in mortality was found between the
two settings. A study performed in Thyolo in 2007
found similar results and reported advanced AIDS-
related complications as the main causes of death in the
health centres [29]. This reinforces the importance of
adequate training in recognition, early initiation of ART
and prompt referral of opportunistic infections, for the
staff involved in ART care delivery in the health centres
[30].
Lessons learnt
Similar treatment outcomes: health centre and
hospital level
The treatment outcomes of both ART programmes con-
firm the feasibility to provide ART care with no inferior
outcomes in health centres, using lower health cadres
and standardised treatment schemes [15,31-35]. This ra-
tionalisation of ART care delivery allowed a significant
increase in patients on ART in both settings, as ART
care became more accessible.
Difference between short and long term retention in
ART care
These findings demonstrate the importance of separat-
ing short from long term retention in care (>12m) as
they are influenced by different factors. This separate
analysis facilitates the identification of the major attri-
tion causes depending on the time on ART and the
adaptation of ART care delivery services accordingly.
During the first months on ART more medical follow-
up is required, especially for symptomatic patients. Once
stable on ART, however, medical care is only needed
sporadically. The main focus should then lie on regular
drug refill and psychosocial support to enable patients
to stay in life-long treatment [36-38]. Adapted and in-
novative ART care delivery models, dissociating med-
ical follow-up from drug refill activities, can be
introduced with medical care mainly offered on the
demand of patients. The drug refill could be spread
out more over time, every three or six months instead
of monthly, and/or organised in- or outside the health
structures (e.g. schools, work places community cen-
tres, etc.) depending on the context and the resources
available [39-41]. Such innovative models may help to
retain patients on treatment and reduce the workload
of the limited number of health staff available in the
health facilities, freeing up time for more severe cases
[15]. However these simplified, public-health orientated
models require that health staff is sufficiently trained
and coached, the community is highly engaged in the
ART delivery care, patients are empowered, ARV drugs
supply is uninterrupted and medical care is readily
available for the few cases that deteriorate [42-44].
Programmes in Mozambique, Malawi and South Africa
with a strong community involvement, offering adher-
ence support through community health workers or
support groups, reported significantly better treatment
outcomes [41,45-47].
Defaulter tracing
To improve the retention in ART care, an effective active
tracing system should be a priority to locate patients
who are late for their appointments, without delay
[48,49]. With the growing cohorts, alternative strategies
to improve patient follow-up and defaulter tracing using
innovative methods, adapted to the context, need to be
explored to improve the cost-effectiveness of the current
strategies. Studies in Zambia and South Africa reported
that up to 19 home visit attempts were required to gen-
erate one single return visit among those patients classi-
fied as late with a cost of over 200US$ per returned
patient [50,51].
To avoid defaulting of patients, it is important to have
good, regular updated records on patients’ contacts and
a person in charge in each health facility to coordinate
the defaulter tracing activities [15,52]. With the growing
number of mobile phone users in the developing world,
mobile phone technology increasingly presents a cheap
and effective method to trace these patients [53]. A pro-
ject in Kenya demonstrated improved adherence in
patients contacted by mobile phone compared to those
who were not [54]. In addition to being a good tracing
system, mobile technology can also strengthen the re-
ferral systems between the different health facilities
and facilitate the exchange of information, to ensure a
continuum of care [55].
Rasschaert et al. BMC Health Services Research 2012, 12:444 Page 9 of 12
http://www.biomedcentral.com/1472-6963/12/444
Monitoring system
The monitoring and evaluation of decentralised ART
care delivery and referral services depends highly on
regular and comprehensive patient follow up. The weak
health system and the lack of motivated human
resources often result in an underestimation of the ac-
tual treatment outcomes.
To enable monitoring of the growing caseload in the
next years, a more simplified and operational monitoring
system will be required, instead of the detailed quarterly
cohort analysis currently performed in most countries
[56,57]. However, to do so, more standardised definitions
and indicators would be useful. Currently a number of
terms, like retention, attrition and lost to follow-up, are
defined ambiguously in the literature.
Limitations and strengths of the study
Several limitations of the study have to be taken into ac-
count. First, there is a lack of information on the
patients lost to follow-up in the programme, as it
remains unclear which proportion of patients may be
self-referred without registration. Second, the data used
was routinely collected and might include some record-
ing errors. Third, the analysis period for the different pa-
tient groups is not identical which might cause a bias in
the overall outcomes. After all, patients initiated on ART
during a later year might benefit from more experienced
health staff in ART care management or better organised
services. Also, as the programme is longer in place,
patients might present themselves at less advanced clin-
ical stages before ART initiation. Fourth, the comparison
of the retention outcomes between the patients accord-
ing to the initiation and follow-up site might be biased
by the selection of patients in each health facility; se-
verely ill patients might be followed in the hospital and
only be referred to the health centres when stabilised on
ART. Fifth, in spite of using cohort data from two differ-
ent rural districts in two different countries we feel
confident about our interpretation of the difference
found between early attrition and late attrition. However,
a different approach and methodology would be re-
quired to explore the lessons learnt from a comparative
case study analysis. The introduction of a complex inter-
vention, such as decentralisation of care may have quite
different implications and lead to different outcomes in
two different countries. In fact in Malawi the decentral-
isation of ART to health centres was carefully planned
and rolled out progressively, while in Zimbabwe it was
done rapidly reacting to serious social-economic chal-
lenges. In this paper we did not focus on the comparison
between the two programmes. Anyhow, we do not think
our generic insights (for example on different retention
rates) need substantial qualification because of the differ-
ent programmes.
The strengths of this study are the large number of
patients who had been on ART for at least 12 months in
the study and the availability of retention outcomes at
36 and 48 months on ART, as very few studies report on
long term outcomes beyond 24 or 36 months. In
addition, the separate presentation of the short and long
term retention rates for the different health facilities is
an innovative way to better identify the causes of attri-
tion according to the time on ART and the ART site.
Conclusions
In conclusion, this analysis highlights a difference in re-
tention rate of patients ≤ and > 12 months on ART, with
a high attrition rate in the initial 12 months on ART,
mainly related to medical problems. After 12 months on
ART, the retention rate flattens, with loss to follow-up
being the main cause of attrition. This suggests the need
for a different approach to ART care delivery, based on
the duration on ART. More innovative ART care delivery
models will be required in the future to enable coping
with the growing caseloads of patients on lifelong ART,
to allow for further ART scale-up and improve retention
in care, by involving the community and introducing
drug delivery points outside the health facilities, depend-
ing on the local context. Moreover, programmes require
improved systems to prevent patients from defaulting or
to trace patients with a missed appointment as soon as
possible, in close collaboration with the community, in
order to retain patients in ART care.
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